J&J Secures Another Indication On Caplyta’s Path To $5bn In Sales

First Label Update Since Closing Intra-Cellular Deal

 
• By Mandy Jackson
  
Q3 sales of Caplyta rose 13.4% from Q2 to $240m (Shutterstock)

More from Scrip

More from Neurological